Evaluation of Adiponectin and Hepcidin with some Biochemical Parameters in Sera of Women with Polycystic Ovary Syndrome
DOI:
https://doi.org/10.23851/mjs.v34i1.1299Keywords:
PCOS, adiponectin, IR, BMI, Hepcidin.Abstract
Polycystic ovarian syndrome (PCOS) is the most recorded endocrinological condition that impacts women throughout their fertile years and causes a variety of clinical symptoms. The study included 60 women with PCOS and 60 women who were matched for age and body mass index (BMI) and excluded the participants refrain from vigorous exercise and drink anything with alcohol or caffeine. were tested levels for IR, insulin, Hepcidin, Adiponectin, lipids profile in control and PCOS. and found Reduced levels (non sig.) of adiponectin have been documented in Iraqi patients with Polycystic Ovary Syndrome. There was an inverse relationship between IR and hepcidin levels in both groups meaning increase in IR (0.001) and decrease in hepcidin (0.001) levels may increase the risk of PCOS. well found that lipid profile (HDL, LDL, TG) that is non-significant but cholesterol high significant 0.001 in patients.
Downloads
References
Norman RJ, Dewaill D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet 2007; 370(9588): 685-97.
Kuçu NK, Var A. Oxidative stress but not endothelial dysfunction exists in non-obese, young group of patients with polycystic ovary Syndrome. Acta Obstet Gynecol Scand 2009; 88(5): 6127.
Trayhurn P, Beattie JH 2001 Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ. Proc Nutr Soc 60:329-339
Maeda K, Okubo K, Shimomura I, Mizuno K, Matsuzawa K 1997 Analysis of an expression profile of genes in the human adipose tissue. Gene 190:227-235.
Saito K, Tobe T, Minoshima S, Asakawa S, Sumiya J, Yoda M, Nakano Y, Shimizu N, Tomita M 1999 Organization of the gene for gelatin-binding protein (GBP28). Gene 229:67-73.
Halleux CM, Takahashi M, Delporte ML, Detry R, Funahashi T, Matsuzawa Y, Brichard SM 2001 Secretion of adiponectin and regulation of apM1 gene expression in human visceral adipose tissue. Biochem Biophys Res Commun 2:1102-1007
Yang WS, Leng CY, Wu TJ, Tanaka S, Funahashi T, Matsuzawa Y, Wang JP, Chen CL, Tai TY, Chuang LM 2002 Synthetic peroxisome proliferator-activated receptor agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 25:376-380
Yang WS, Lee WJ, Funahashi T, Tanaka S, Matsazawa Y, Chao CL, Chen CL, Tai TY, Chuang LM 2001 Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 86:3815-3819
Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa JI, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, YamashitaS, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsu- zawa Y 1999 Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257:79-83
Yang WS, Lee WJ, Funahashi T, Tanaka S, Matsazawa Y, Chao CL, Chen CL, Tai TY, Chuang LM 2001 Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metabol86:3815-3819.
Matsubara M, Maruoka S, Katayose S 2002 Decreased plasma adiponectin concentrations in women with dyslipidemia. J Clin Endocrinol Metab 87:2764- 2769.
Kondo H, Shimomura I, Matsukawa Y, Takahashi M, Matsuda M, Ouchi N, Kihara S, Kanamoto T, Sumitsuji S, Funahashi T, Matsuzawa Y 2002 Association of adiponectin mutation with type 2 diabetes. Diabetes 51:2325-2328.
Kazumi T, Kawaguchi A, Sakai K, Hirano T, oshino G 2002 Young men with high-normal blood pressure have lower serum adiponectin, smaller LDL size, and higher elevated heart rate than those with optimal blood pressure. Dia betes Care 25:971-976.
Castagna A, Campostrini N, Zaninotto F, Girelli D.Hepcidin assay in serum by SELDI-TOF-MS and other approaches. J Proteomics 2009; 73:527-36.
Wang H, Li H, Jiang X, Shi W, Shen Z, Li M. Hepcidin is directly regulated by insulin and plays an important role in iron overload in streptozotocin-induced diabetic rats. Diabetes 2014; 63:1506-18
Luque-Ramírez M, Álvarez-Blasco F, Alpañés M, Escobar-Morreale HF. Role ofdecreased circulating hepcidin concentrations in the iron excess of women with the polycystic ovary syndrome. J Clin Endocrinol Metab 2011; 96:846-52.
Sam AH, Busbridge M, Amin A, Webber L, White D,Franks S, et al. Hepcidin levels in diabetes mellitus andpolycystic ovary syndrome. Diabet Med 2013; 30:1495-9.
Datz C, Felder TK, Niederseer D, Aigner E. Iron homeostasis in the metabolic syndrome. Eur J Clin Invest 2013; 43:215-24.
Luque-Ramírez M, Alvarez-Blasco F, Botella-CarreteroJI, Sanchón R, San MillánJL, Escobar-Morreale HF.Increased body iron stores of obese women withpolycystic ovary syndrome is a consequence of insulin resistance and hyperinsulinism and are not a result of reduced menstrual losses. Diabetes Care 2007; 30:2309-13.
Ahmed HH, Fadl NN, Kotob SE. Impact of Long-Term Metformin Therapy on Hepcidin and Iron Status in Type II Diabetic Patients. International Journal of Pharmaceutical and Clinical Research2015; 7:185-93.
Lagaly DV, Aad PY, Grado-Ahuir JA, Hulsey LB, Spicer LJ. Role of adiponectin in regulating ovarian theca and granulosa cell function. Mol Cell Endocrinol. 2008;284(1-2):38-45.
Comim FV, Gutierrez K, Bridi A, Bochi G, Chemeris R, Rigo ML, et al. Effects of Adiponectin Including Reduction of Androstenedione Secretion and Ovarian Oxidative Stress Parameters In Vivo. PLoS One. 2016;11(5): e0154453
Azziz R, Carmina E, Chen Z, Dunaif A, Laven JSE, Legro RS, et al. Polycystic ovary syndrome. Nat Rev Dis Primers. 2016;2(1):16057.
Amer H, Abo‑Shady R, Elaziz D, Khattab Y. The role of serum adiponectin levels in women with polycystic ovarian syndrome. Egypt J Hosp Med. 2017; 68:837-44.
Doh E, Mbanya A, Kemfang‑Ngowa JD, Dohbit S, Tchana‑Sinou M, Fou‑ mane P, et al. The relationship between adiposity and insulin sensitivity in african women living with the polycystic ovarian syndrome: a clamp study. Int J Endocrinol. 2016; 2016:1-6.
Ehrmann DA, et al. Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non‑insulin‑ dependent diabetes mellitus. J Clin Invest. 1995; 96:520-7.
Ziemke F, Mantzoros CS. Adiponectin in insulin resistance: lessons from translational research. Am J Clin Nutr. 2010;91(1):258S‑261S.
Orio F, Palomba S, Cascella T, Milan G, Mioni R, Pagano C, et al. Adiponectin levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2003;88(6):2619-23.
Lecke SB, Mattei F, Morsch DM, Spritzer PM. Abdominal subcutaneous fat gene expression and circulating levels of leptin and adiponectin in polycystic ovary syndrome. Fertil Steril. 2011;95(6) :2044-9.
Sam AH, Busbridge M, Amin A, Webber L, White D, Franks S, Martin NM, Sleeth M, Ism ail NA, Mat Daud N, Papamargaritis D, Le Roux CW, Chapm an RS, Frost G, Bloom SR, Murphy KG. Hepcidin levels in diabetes mellitus and polycystic ovary syndrome. diabetic Med 2013; 30: 1495-1499.
Aroda V, Ciaraldi TP, Chang S‑A, Dahan MH, Chang RJ, Henry RR. Circulating and cellular adiponectin in polycystic ovary syndrome: relationship to glucose tolerance and insulin action. Fertil Steril. 2008;89(5):1200-8
Goldstein A, Jutel A, Drew K (2014): Social issues in diagnosis. Baltimore, MD: John Hopkins University Press.
Pagotto U, Gambineri A, Vicennati V et al. (2002): Plasma ghrelin, obseity, and the polycystic ovary syndrome: Correlation with insulin resistance and androgen levels. J Clin Endocrinol Metab., 87: 5625-9.
Khomami MB, Tehrani FR, Hashemi S et al. (2015): Of PCOS symptoms, hirsutism has the most significant impact on the quality of life of Iranian women. PLoS ONE, 10: e0123608.
Jones GL, Hall JM, Lashen HL et al. (2011): Health related quality of life among adolescents with polycystic ovary syndrome. Journal of Obstetric, Gynecologic, and Neonatal Nursing, 40: 577-588.
Jayasekara RS (2012): Focus groups in nursing research: Methodological perspectives. Nursing Outlook, 60: 411-6
Downloads
Key Dates
Published
Issue
Section
License
Copyright (c) 2023 Al-Mustansiriyah Journal of Science
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
(Starting May 5, 2024) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution (CC-BY) 4.0 License that allows others to share the work with an acknowledgement of the work’s authorship and initial publication in this journal.